A new national survey shows that Americans overwhelmingly support the FDA’s Critical Path Initiative. The survey was comprised of a nationally representative sample of 1,049 adults and conducted by Opinion Research Corporation. It was commissioned by the Center for Medicine in the Public Interest and iGuard Inc.
When asked about Critical Path, nine in 10 Americans expressed support. The Critical Path Initiative was launched by the FDA in 2004 to streamline drug development.
The survey also examined attitudes regarding key features of Critical Path. When asked about the FDA's efforts to expand the use of biomarkers to identify which drugs are best for individual patients, 78 percent of those surveyed were supportive.
The survey also found that 77 percent of the public supports partnerships between private companies, the FDA, and academics to create new approaches to drug evaluation and development.
And nearly 80 percent want their member of Congress to support Critical Path.
Survey respondents also expressed support for a voluntary, confidential, online portal where patients could share information about their reactions to different drugs. 87 percent said such a program would boost their confidence in drug safety, and 50 percent said they would take part.
Day in and day out, congressional lawmakers bash the FDA. That may score political points, but the public’s support for this program should send a strong message to Congress: Don’t cut funding from the Critical Path Initiative.
For the full report, click below
http://www.cmpi.org
And then under "Reports" click on "Critical Path National Research Report."
When asked about Critical Path, nine in 10 Americans expressed support. The Critical Path Initiative was launched by the FDA in 2004 to streamline drug development.
The survey also examined attitudes regarding key features of Critical Path. When asked about the FDA's efforts to expand the use of biomarkers to identify which drugs are best for individual patients, 78 percent of those surveyed were supportive.
The survey also found that 77 percent of the public supports partnerships between private companies, the FDA, and academics to create new approaches to drug evaluation and development.
And nearly 80 percent want their member of Congress to support Critical Path.
Survey respondents also expressed support for a voluntary, confidential, online portal where patients could share information about their reactions to different drugs. 87 percent said such a program would boost their confidence in drug safety, and 50 percent said they would take part.
Day in and day out, congressional lawmakers bash the FDA. That may score political points, but the public’s support for this program should send a strong message to Congress: Don’t cut funding from the Critical Path Initiative.
For the full report, click below
http://www.cmpi.org
And then under "Reports" click on "Critical Path National Research Report."
